-- Abstract #87
Poster presentation: ER and PR Assessment in ECOG 2197; Comparison of
Locally Determined IHC with Centrally Determined IHC and Quantitative
Presenter: Sunil S. Badve, M.D.
Summary: A comparison of IHC and quantitative RT-PCR by Oncotype DX
demonstrated a high degree of agreement for measuring ER, PR and HR
-- Abstract #106
Poster presentation: Use of Estrogen Receptor (ER) Expression by
Quantitative RT-PCR to Identify an ER Negative Subgroup by IHC Who
Might Benefit from Hormonal Therapy
Presenter: Luca Gianni, M.D.
Summary: Independent investigators compared quantitative RT-PCR by
Oncotype DX, DNA microarrays, and IHC for measuring ER status.
-- Abstract #27
Oral presentation: Association of Individual Genes with
Risk of Relapse in Operable Breast Cancer: Analysis of E2197
Presenter: Joseph Sparano, M.D.
Summary: Further examination of the Eastern Cooperative Oncology Group
E2197 study identifies multiple genes, including the 21 in Oncotype DX,
that affect the recurrence risk following chemotherapy treatment.
About Oncotype DX(TM)
Oncotype DX represents the first diagnostic multi-gene expression test
service commercially available that has clinical evidence validating its
ability to predict the likelihood of breast cancer recurrence, the
likelihood of patient survival within 10 years of diagnosis and the
likelihood of chemotherapy benefit. Oncotype DX has been extensively
evaluated in multiple independent studies involving more than 2,600 breast
cancer patients, including a large validation study published in The New
England Journal of Medicine and a chemotherapy benefit study published in
the Journal of Clinical Oncology. To date, over 6,000 physicians have
ordered a cumulative total of more than 33,000 tests and approximat
|SOURCE Genomic Health, Inc.|
Copyright©2007 PR Newswire.
All rights reserved